• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Costco Adds Phexxi To Member Prescription Program

    1/10/23 8:40:10 AM ET
    $COST
    $EVFM
    Department/Specialty Retail Stores
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COST alert in real time by email

    Evofem Biosciences, Inc. (OTCQB:EVFM) today announced that Phexxi® (lactic acid, citric acid, potassium bitartrate) has been added to the Costco Member Prescription Program, giving millions of additional women access to this innovative hormone-free contraceptive.

    (EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

    "We are pleased to partner with Costco, the largest warehouse club and third-largest retailer in America, to expand Phexxi's footprint in the cash space," said Saundra Pelletier, Chief Executive Officer of Evofem. "This program enables Costco members with no insurance or whose plans have denied coverage to fill their Phexxi prescriptions at a reduced cost."

    The Costco Member Prescription Program is a prescription drug discount card program that provides eligible Costco members and their eligible dependents the ability to obtain lower prices on Phexxi and other participating drugs at participating pharmacies.

    Costco members who are uninsured and want to pay cash for their Phexxi prescription, or who have been denied coverage by their insurer, may use this program to fill their Phexxi prescriptions for less than the typical cash pay cost.

    The pricing available through the discount card applies at their local Costco pharmacies, Costco mail order and thousands of participating neighborhood pharmacies. 

    Get the next $COST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COST
    $EVFM

    CompanyDatePrice TargetRatingAnalyst
    Costco Wholesale Corporation
    $COST
    1/8/2026Buy
    Deutsche Bank
    Costco Wholesale Corporation
    $COST
    1/5/2026$1000.00Neutral → Outperform
    Mizuho
    Costco Wholesale Corporation
    $COST
    12/24/2025Neutral → Buy
    Northcoast
    Costco Wholesale Corporation
    $COST
    12/15/2025$769.00Neutral → Sell
    Roth Capital
    Costco Wholesale Corporation
    $COST
    11/3/2025$1130.00 → $1050.00Outperform
    Oppenheimer
    Costco Wholesale Corporation
    $COST
    10/15/2025$1115.00Buy
    BTIG Research
    Costco Wholesale Corporation
    $COST
    9/18/2025Peer Perform
    Wolfe Research
    Costco Wholesale Corporation
    $COST
    8/5/2025Buy → Hold
    Erste Group
    More analyst ratings

    $COST
    $EVFM
    SEC Filings

    View All

    Costco Wholesale Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - COSTCO WHOLESALE CORP /NEW (0000909832) (Filer)

    1/21/26 4:16:10 PM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    Evofem Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

    1/12/26 5:01:20 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Costco Wholesale Corporation

    144 - COSTCO WHOLESALE CORP /NEW (0000909832) (Subject)

    12/30/25 1:17:50 PM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    $COST
    $EVFM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank initiated coverage on Costco

    Deutsche Bank initiated coverage of Costco with a rating of Buy

    1/8/26 10:58:24 AM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    Costco upgraded by Mizuho with a new price target

    Mizuho upgraded Costco from Neutral to Outperform and set a new price target of $1,000.00

    1/5/26 8:29:47 AM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    Costco upgraded by Northcoast

    Northcoast upgraded Costco from Neutral to Buy

    12/24/25 11:52:07 AM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    $COST
    $EVFM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Costco Wholesale Corporation Reports January Sales Results

    ISSAQUAH, Wash., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation ("Costco" or the "Company") (NASDAQ:COST) today reported net sales of $21.33 billion for the retail month of January, the four weeks ended February 1, 2026, an increase of 9.3 percent from $19.51 billion last year. Net sales for the first 22 weeks were $123.16 billion, an increase of 8.5 percent from $113.55 billion last year. Comparable sales for the periods ended February 1, 2026, were as follows:  4 Weeks 22 WeeksU.S.5.8% 5.9%Canada11.4% 7.8%Other International9.5% 9.5%    Total Company7.1% 6.6%Digitally-Enabled34.4% 21.8%     Comparable sales excluding the impacts from changes in gasoline prices and forei

    2/4/26 4:15:00 PM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    Costco Wholesale Corporation Announces Quarterly Cash Dividend

    ISSAQUAH, Wash., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation ("Costco" or the "Company") (NASDAQ:COST) today announced that its Board of Directors has declared a quarterly cash dividend on Costco common stock of $1.30 per share. The quarterly dividend is payable February 13, 2026, to shareholders of record at the close of business on January 30, 2026. Costco currently operates 923 warehouses, including 633 in the United States and Puerto Rico, 114 in Canada, 42 in Mexico, 37 in Japan, 29 in the United Kingdom, 20 in Korea, 15 in Australia, 14 in Taiwan, seven in China, five in Spain, three in France, two in Sweden, and one each in Iceland, and New Zealand. Costco also o

    1/15/26 4:15:00 PM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    Costco Wholesale Corporation Reports December Sales Results

    ISSAQUAH, Wash., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation ("Costco" or the "Company") (NASDAQ:COST) today reported net sales of $29.86 billion for the retail month of December, the five weeks ended January 4, 2026, an increase of 8.5 percent from $27.52 billion last year. Net sales for the first eighteen weeks were $101.83 billion, an increase of 8.3 percent from $94.04 billion last year. Comparable sales were as follows:   5 Weeks 18 Weeks  U.S.6.0% 5.9%  Canada8.4% 7.0%  Other International10.6% 9.5%        Total Company7.0% 6.6%        Digitally-Enabled18.9% 19.6%        Comparable sales excluding the impacts from changes in gasoline prices and foreign exchange w

    1/7/26 4:15:00 PM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    $COST
    $EVFM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Raikes Jeffrey S gifted 5,115 shares, decreasing direct ownership by 31% to 11,293 units (SEC Form 4)

    4 - COSTCO WHOLESALE CORP /NEW (0000909832) (Issuer)

    1/28/26 6:46:11 PM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    Executive Vice President Jones Teresa A. gifted 300 shares, decreasing direct ownership by 7% to 3,928 units (SEC Form 4)

    4 - COSTCO WHOLESALE CORP /NEW (0000909832) (Issuer)

    1/28/26 6:43:58 PM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    Executive Vice President Jones Teresa A. sold $838,318 worth of shares (850 units at $986.26), decreasing direct ownership by 17% to 4,228 units (SEC Form 4)

    4 - COSTCO WHOLESALE CORP /NEW (0000909832) (Issuer)

    1/23/26 4:53:38 PM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    $COST
    $EVFM
    Financials

    Live finance-specific insights

    View All

    Costco Wholesale Corporation Announces Quarterly Cash Dividend

    ISSAQUAH, Wash., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation ("Costco" or the "Company") (NASDAQ:COST) today announced that its Board of Directors has declared a quarterly cash dividend on Costco common stock of $1.30 per share. The quarterly dividend is payable February 13, 2026, to shareholders of record at the close of business on January 30, 2026. Costco currently operates 923 warehouses, including 633 in the United States and Puerto Rico, 114 in Canada, 42 in Mexico, 37 in Japan, 29 in the United Kingdom, 20 in Korea, 15 in Australia, 14 in Taiwan, seven in China, five in Spain, three in France, two in Sweden, and one each in Iceland, and New Zealand. Costco also o

    1/15/26 4:15:00 PM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    Costco Wholesale Corporation Reports First Quarter Fiscal Year 2026 Operating Results

    ISSAQUAH, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation ("Costco" or the "Company") (NASDAQ:COST) today announced its operating results for the first quarter of fiscal 2026 (twelve weeks), ended November 23, 2025. Net sales for the first quarter increased 8.2 percent, to $65.98 billion from $60.99 billion last year. Comparable sales for the first quarter fiscal 2026 were as follows:   12 Weeks 12 Weeks    Adjusted* U.S.5.9% 5.9% Canada6.5% 9.0% Other International8.8% 6.8%      Total Company6.4% 6.4%      Digitally-Enabled20.5% 20.5%  *Excluding the impacts from changes in gasoline prices and foreign exchange. Net income for the quarter was $2,001 million, $4.50

    12/11/25 4:15:00 PM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary

    Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update

    -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter -- -- Delivered $1.0 Million of Operating Income in Q3 2025 -- SAN DIEGO, Nov. 13, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and nine-month periods ended September 30, 2025 and provided a business update. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Sales rebounded in the thi

    11/13/25 4:05:00 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COST
    $EVFM
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

    4/17/25 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

    Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice

    10/29/24 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)

    Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as

    8/26/24 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COST
    $EVFM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

    SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

    2/14/24 2:14:48 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

    SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

    2/14/23 11:24:47 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Costco Wholesale Corporation (Amendment)

    SC 13G/A - COSTCO WHOLESALE CORP /NEW (0000909832) (Subject)

    2/9/23 11:15:26 AM ET
    $COST
    Department/Specialty Retail Stores
    Consumer Discretionary